GlassScriptPhysician profile
Emily D Cunningham
NPI 1376141986
$3,564.54
in general payments reported to CMS, 2019-2025
19 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $332 · 2023: $459 · 2024: $919 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $929.73 | 2022-2025 | |
| Madrigal Pharmaceuticals | $445.63 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $432.86 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Janssen Pharmaceuticals, INC | $392.60 | 2021-2022 | |
| Ardelyx, INC. | $303.15 | 2025 | Ibsrela |
| Cvrx, INC. | $178.39 | 2024 | Barostim Neo System |
| Phathom Pharmaceuticals, INC. | $162.06 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $125.00 | 2023 | Gimoti |
| Mallinckrodt Hospital Products INC. | $123.29 | 2024 | Terlivaz |
| Silk Road Medical, INC. | $112.91 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Lilly USA, LLC | $105.84 | 2024 | Omvoh |
| Fresenius Kabi USA, LLC | $51.03 | 2024-2025 | Idacio |
| Ironwood Pharmaceuticals, INC | $49.86 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $37.92 | 2023-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $34.33 | 2025 | Vowst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.45 | 2024 | Entyvio |
| Pfizer INC. | $21.44 | 2024 | |
| Genzyme Corporation | $20.58 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.47 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.